Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.57 |
| ▸ | RXRB | P28702 | 2/20 | 0.57 |
| ▸ | RXRG | P48443 | 2/20 | 0.57 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 12/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23032636 | 0.87 | RXRA (0.44) | RXRARXRBRXRGCTSSCTSK | |
| SCHEMBL2415055 | 0.85 | RXRA (0.59) | RXRARXRBRXRGCTSSCTSK | |
| SCHEMBL30488261 | 0.85 | RXRA (0.59) | RXRARXRBRXRGCTSSCTSK | |
| SCHEMBL932902 | 0.85 | RXRA (0.56) | RXRARXRBRXRGCTSSCTSK | |
| SCHEMBL247961 | 0.85 | CSNK2A1 (0.59) | RXRARXRBRXRGCTSSCTSK | |
| SCHEMBL2019451 | 0.85 | RXRA (0.59) | RXRARXRBRXRGCTSSCTSK | |
| SCHEMBL26179843 | 0.84 | RXRA (0.54) | RXRARXRBRXRGCTSSCTSK | |
| SCHEMBL12013165 | 0.81 | S1PR1 (0.46) | RXRARXRBRXRGCTSSCTSK | |
| SCHEMBL17014923 | 0.79 | RXRA (0.57) | RXRARXRBRXRGCTSSCTSK | |
| SCHEMBL16606256 | 0.78 | CSNK2A1 (0.49) | CSNK2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284399-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284399-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-9085581-B2 | Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof | ARENA PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085581-B2 | Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof | ARENA PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20120329848-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329848-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | S1PR1, S1PR5, S1PR2 | RXRA 1023/4885RXRB 1049/4885RXRG 1223/4885 |
| US-20150284399-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | S1PR1, S1PR5, S1PR2 | RXRA 1054/4885RXRB 1087/4885RXRG 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.